Should You Buy Viking Therapeutics Before Nov. 5?

Viking Therapeutics (VKTX) is progressing its weight loss candidate, VK2735, with an injectable version in Phase 3 trials and an oral version in Phase 2, positioning it in the high-demand GLP-1/GIP agonist market. After an initial surge on positive Phase 2 results and subsequent correction, the stock has recently gained 16% ahead of upcoming poster presentations at ObesityWeek and the American Heart Association Scientific Sessions in early November. These presentations will detail Phase 3 study designs and VK2735's impact on prediabetes and metabolic syndrome, though they are not expected to trigger significant stock movement as they are not new trial data releases.

Analysis

Viking Therapeutics (VKTX) is strategically positioned in the high-demand GLP-1/GIP receptor agonist market with its weight loss candidate, VK2735, currently in Phase 3 trials for an injectable version and Phase 2 for an oral formulation. The Phase 2 study demonstrated robust efficacy, achieving up to 13.1% average weight loss after 13 weeks without a plateau, underscoring its potential in a market projected to reach $100 billion by decade-end. This places VKTX as a significant emerging player alongside established pharmaceutical giants like Novo Nordisk and Eli Lilly.

VKTX shares experienced a substantial surge of over 120% following initial positive Phase 2 results but subsequently corrected, declining 47% over the past year, attributed to profit-taking or market disappointment regarding a potential acquisition rather than adverse company news. However, the stock has recently shown renewed positive momentum, climbing 16% over the last three months, indicating growing investor confidence.

Upcoming catalysts include poster presentations at ObesityWeek 2025 and the American Heart Association Scientific Sessions 2025 in early November. These presentations will detail VK2735's impact on prediabetes and metabolic syndrome, alongside the design of its Phase 3 studies for obesity and type 2 diabetes. While these are not expected to trigger significant short-term stock movements, they will reinforce the candidate's broader cardiometabolic benefits, which are critical for future reimbursement and market adoption.

The continued progression of VK2735 into late-stage trials, supported by strong Phase 2 data and the potential for additional cardiometabolic indications, suggests a favorable long-term outlook for Viking Therapeutics. The overall sentiment surrounding VKTX is strongly positive, reflecting the promising nature of its pipeline and market opportunity.

Key Decisions for Investors

• Consider initiating or adding to a long position in VKTX, leveraging the promising late-stage pipeline and the substantial growth potential within the weight loss market.
• Monitor the detailed information released from the upcoming medical conference presentations for further insights into VK2735's cardiometabolic benefits and Phase 3 trial designs, which could strengthen the long-term investment thesis.
• Recognize that while near-term catalysts may not cause immediate significant price spikes, the long-term value proposition of VKTX in a rapidly expanding market warrants a patient, strategic accumulation of shares.